Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$420,479
+$10,651 QoQ
Shares Held
2,683
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#967
of 1,603 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Gotham Asset Management, LLC holds $386,755,559 across 13 Drug Manufacturers - General names. NVS ranks #11 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
528,937 | $67,968,404 | |
| 2 | BIIB |
Biogen Inc.
|
279,900 | $60,475,194 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
892,969 | $51,452,873 | |
| 4 | JNJ |
Johnson & Johnson
|
200,512 | $50,924,032 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
381,851 | $48,243,055 | |
| 6 | ABBV |
AbbVie Inc.
|
108,867 | $27,395,291 | |
| 7 | LLY |
ELI LILLY & Co
|
21,971 | $26,352,678 | |
| 8 | PFE |
Pfizer Inc
|
916,205 | $22,062,216 |
All Filings in NVS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $420,479 | 2,683 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $409,828 | 2,683 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $379,831 | 2,755 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $250,837 | 1,956 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $213,582 | 1,765 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||